Cyclerion Therapeutics is currently under investigation for potential fiduciary breaches related to its all-stock merger with Korsana Biosciences. Concerns are mounting regarding whether the board adequately fulfilled its responsibilities to shareholders, especially given that pre-merger Cyclerion owners are expected to retain only 1.5% of the newly formed entity. The deal's terms, including penalties on competing offers and the distribution of contingent value rights, are also under scrutiny. Despite recent stock volatility, with shares trading at $6.11 after a prior surge of 294.19%, the ongoing investigations have cast doubt on the merger's fairness for investors.
Click a month on the chart to update the report below.